Immunex Corporation

Carl J March

David L Urdal

Steven K Dower

David J Cosman

Douglas Pat Cerretti

M Patricia Beckmann

Bruce A Mosley

Linda S Park

Rejean Idzerda

John Ernest Sims

Charles Rauch

Roy A Black

Paul J Conlon, Iii

Thomas P Hopp

Shirley R Kronheim

Alf D Larsen

Susan L Bektesh

Kenneth H Grabstein

Virginia L Price

Diane Y Mochizuki

Cosman

John E Sims

A metalloprotease that converts TNF-&#x3b1; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.

Antibodies that bind TNF-&#x3b1; converting enzyme

Methods and comnositions related to antibodies that bind to mammalian Tnterleulcin-4 recentor proteins are disclosed.

Antibodies to Interleukin-4 receptors and uses thereof

Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Antibodies to interleukin-4 receptors and uses thereof

A metalloprotease that converts TNF-&agr; from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.

TNF-&agr; converting enzyme

Interleukin-4 receptors

The present invention provides monoclonal antibodies and binding proteins which specifically bind to the IL-1 receptor. Also provided are methods for detecting IL-1 receptors on cells, and for detecting soluble IL-1 receptors in serum.

Antibodies to interleukin-1 receptors

TNF-a converting enzyme

DNA encoding interleukin-4 receptors

A metalloprotease that converts TNF-.alpha. from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.

TNF-.alpha. converting enzyme

Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Use of interleukin-4 receptors to inhibit biological responses mediated

Growing community of inventors

Bainbridge Island, WA, United States of America

Carl J March